BTT Medical opens first-in-human trial of fever-induction device
BTT Medical Institute and its parent company btt Corp. have opened a first-in-human clinical safety trial of the Abreu BTT 700 Temperature Management System, a noninvasive device designed to raise body temperature into a controlled fever range using what the company describes as brain-guided thermodynamic control. The trial is registered on ClinicalTrials.gov under identifier NCT07564440.
The announcement follows the November 2025 publication of a peer-reviewed case report in the journal Diseases, which described what the authors characterised as a total reversal of amyotrophic lateral sclerosis in a single 56-year-old patient following treatment with the BTT 700 protocol. The patient reportedly no longer met diagnostic criteria for ALS, discontinued ALS-specific medications, and remained free of clinical relapse more than a year after treatment. Independent EMG studies and blood biomarker analyses, the company says, corroborated the reported neurological recovery.
Scientific context and caveats
The claims in that case report are extraordinary by any clinical standard. ALS is widely considered irreversible, and the published medical literature contains no confirmed precedent for complete disease reversal of the kind described. A single case report, by design, cannot establish causation, and the field will require prospective controlled trial data before drawing conclusions about efficacy. The company's framing of its approach as a "reengineering" of the 1927 Nobel Prize-recognised malarial fever therapy of Julius Wagner-Jauregg adds historical colour but does not confer clinical validation. Readers should note that the current trial is a safety study only; it is not designed to demonstrate efficacy, and no efficacy claims can be drawn from its results.
The BTT 700 system received FDA 510(k) clearance in 2010 for temperature monitoring via what the company terms the Brain Temperature Tunnel, a periorbital measurement site identified by founder M. Marc Abreu during research at Yale University in the early 2000s. The investigational use now being trialled, therapeutic fever induction for neurological disease, goes substantially beyond the cleared indication and is the subject of this new safety evaluation.
Market and regulatory landscape
Interest in heat shock protein biology as a therapeutic target in neurodegeneration is genuine and growing. Several academic and early-stage commercial groups are investigating HSP90 inhibitors, HSF1 activators, and other chaperone-related strategies in ALS, Alzheimer's disease, and Parkinson's disease, though none has yet reached late-stage clinical development for ALS specifically. The noninvasive route that BTT proposes, if it can be shown to reliably modulate central heat shock responses without harm, would represent a differentiated manufacturing and delivery profile relative to small-molecule or biological approaches.
The broader ALS therapeutic landscape remains sparse. Riluzole and edaravone are approved but confer modest benefit, and the 2023 approval of tofersen addresses only SOD1-mutation carriers. The commercial and scientific case for a new mechanism is clear; the evidentiary bar the BTT 700 must clear is correspondingly high. The safety trial now under way is a necessary first step, but investors and clinicians should treat the single case report as hypothesis-generating rather than practice-changing.